Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,617

Employees2,617

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,617

Employees2,617

INCY Key Statistics

Market cap

20.13B

Market cap20.13B

Price-Earnings ratio

17.11

Price-Earnings ratio17.11

Dividend yield

—

Dividend yield—

Average volume

1.82M

Average volume1.82M

High today

$103.42

High today$103.42

Low today

$101.03

Low today$101.03

Open price

$101.57

Open price$101.57

Volume

813.54K

Volume813.54K

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $102.56. The company's market cap stands at 20.13B, with a P/E ratio of 17.11.

On 2026-01-26, Incyte(INCY) stock moved within a range of $101.03 to $103.42. With shares now at $102.56, the stock is trading +1.5% above its intraday low and -0.8% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 813.54K, versus its average volume of 1.82M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

Simply Wall St 2d

Assessing Incyte Valuation After Wells Fargo Rating Cut And Cooler Near Term Catalysts

Advertisement What triggered the latest move in Incyte (INCY)? Wells Fargo’s decision to cut its rating on Incyte (INCY) from Overweight to Equal Weight, alon...

Simply Wall St 5d

Is Incyte Pricing Reflect Its Strong 1-Year Rally And DCF Upside Potential

If you are wondering whether Incyte's recent share price puts it at a bargain or a stretch, this article walks through what the numbers are currently saying abo...

TipRanks 6d

Wells downgrades Incyte to Equal Weight on lack of catalysts

Wells Fargo downgraded Incyte (INCY) to Equal Weight from Overweight with a price target of $107, down from $116. The firm says its upgrade thesis has largely p...

Analyst ratings

50%

of 28 ratings

Buy

39.3%

Hold

50%

Sell

10.7%

More INCY News

TipRanks 6d

Incyte downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Incyte (INCY) to Equal Weight from Overweight with a $107 price target Published first on TheFly – the ultimate source for real-time, ma...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.